Athersys has developed its MultiStem cell therapy for COVID-19 Acute respiratory distress syndrome (ARDS). Athersys CEO Gil Van Bokkelen, PhD, and CFO Ivor Macleod, recently spoke to Contagion providing background on the company and their MultiStem therapy.
In this conversation, Jones discussed looking at the benefits around choosing 1 specific therapy for treatment.
Research finds that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.
This study explores HLA-E as a target to activate the immune system in HBV infection, identifying a stable peptide, Env371-379 L6I, that effectively triggers T-cell…
With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon,…
Using faecal microbiota transplantation within the CGA framework further enhanced survival and care efficiency.
Mild reactions were experienced in 46% of recipients.
New research using advanced MRI techniques explores how impaired pulmonary gas exchange may contribute to cognitive impairments in Long COVID patients, offering insights for potential…
Recent data shows a 1 in 5 risk of unvaccinated house members transmitting the respiratory virus to other nonimmunized members.
CDPH advises consuming pasteurized milk, which kills the virus, while the state increases testing and monitoring following 29 confirmed human cases of H5N1 linked to…
It is not only about cooking the food to the correct temperature, but also how long the food should sit out, and safe storage after…
